NextCure Inc (NXTC)
NASDAQ:NXTC
Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$2.83 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$22.39M
Enterprise Value$5.33M
Total Cash (Recent Filing)$29.74M
Total Debt (Recent Filing)$3.88M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jul 30, 2026EPS Estimate
-1.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.07
Shares Outstanding3,612,096
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.82
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$25.00Price Target Upside82.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-9.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage EfficacyA 55% objective response rate in heavily pretreated gynecologic cancers provides durable proof-of-concept for SIM0505, materially de-risking the program versus preclinical stages. This clinical validation supports potential partnerships, smoother enrollment in later trials, and greater probability of future licensing or commercialization revenue.
Low LeverageModest debt relative to equity reduces near-term refinancing and solvency risk for a clinical-stage biotech that relies on capital markets. Low leverage gives management flexibility to raise equity or structured financing for development programs without immediate pressure from large interest or principal obligations.
Narrowing Operating LossesA meaningful reduction in operating losses signals improving cost control or more efficient development spend, which can extend runway per dollar raised. Sustained narrowing of losses supports longer-term sustainability of R&D programs and reduces the frequency and size of future dilutive financings if the trend continues.
Bears Say
No Product RevenueAbsence of product sales leaves the company structurally dependent on external financing and collaboration deals to fund operations. Until regulatory approvals or commercial partnerships produce recurring revenue, the business lacks internally generated cash flows, keeping long-term sustainability contingent on successful trials and capital markets.
Persistent Negative Cash FlowSustained ~-$50M annual negative operating/free cash flow creates ongoing financing needs that constrain strategic flexibility. Continued cash burn can force prioritization of programs, slow development timelines, and increase likelihood of dilutive equity raises or partnership deals on less favorable terms absent a material change in cash generation.
Finite Cash RunwayA runway limited to Q1 2027 imposes a structural financing cliff that will likely require capital raises or strategic partnerships before key inflection points. That timing pressure can lead to dilution or hurried deal terms, and it constrains the company's ability to fund multiple simultaneous development paths without external support.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $2.83 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $22.39M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Jul 30, 2026 which is in 58 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Apr 30, 2026. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.105 by $0.235.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.91.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,612,096 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.105. Following the earnings report the stock price went up 3.02%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$25.00
▲(82.08% Upside)
Technical Analysis
Ownership Overview
―
Insiders
9.96% Mutual Funds
48.82% Other Institutional Investors
36.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---